1179PDNatural dendritic cell vaccinations generate immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
ConclusionsImmunotherapy with primary DC subsets induced functional antigen-specific T cells. The presence of functional antigen-specific T cells correlated with longer rPFS.Clinical trial identificationNCT02692976.Legal entity responsible for the studyJolanda de Vries and Winald Gerritsen.FundingThis work was supported by Stichting Afweer Tegen Kanker, Dr. Paul A.J. Speth Stichting and H2020 EU grant PROCROP (grant No 635122). Carl G. Figdor received ERC Adv Grant PATHFINDER (269019) and the NWO Spinoza grant. I. Jolanda M. de Vries received NWO-Vici grant (918.14.655).DisclosureAll authors have declared no conflicts of interest.
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 10Author(s): R. Rodrigues Fonseca, R. Lains Mota, I. Peyroteo, A. Bilé Silva, J.C. Santos, F. Alpoim Lopes, A. Covita, A. Canhoto, P. Monteiro, R. Nogueira, L. Abranches Monteiro
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 10Author(s): D. Meijer, B.H.E. Jansen, M. Wondergem, S. Srbljin, A.E. Vellekoop, A. Keizer, O.S. Hoekstra, J.A. Nieuwenhuijzen, D.E. Oprea-Lager, A.N. Vis
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 10Author(s): B.H.E. Jansen, M. Wondergem, F.M. Van Der Zant, T.M. Van Der Sluis, R.J.J. Knol, L.W.M. Van Kalmthout, O. Hoekstra, R.J.A. Van Moorselaar, D.E. Oprea-Lager, A.N. Vis
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 10Author(s): G. Lughezzani, J.G. Pereira, A. Sánchez, F. Staerman, H. Cash, L. Lopez, J. Rouffilange, R. Gaston, E. Klein, R. Abouassaly, A. El-Shefai, L. Klotz, G. Eure
Purpose High-intensity interval training (HIIT) is a time-efficient and promising tool for enhancing physical fitness. However, there is lack of research concerning safety and feasibility of HIIT in cancer survivors. Therefore, two different HIIT protocols were investigated in terms of safety, feasibility, and acute exercise responses. Methods Forty cancer survivors (20 breast and 20 prostate cancer survivors, 62.9 ± 9.2 yr, BMI 27.4 ± 3.9 kg·m−2, 6 to 52 wk after the end of primary therapy) completed a maximal cardiopulmonary exercise test and two HIIT protocols on a cycle ergometer: 10 &ti...
Publication date: November 2019Source: Journal of Comparative Pathology, Volume 173Author(s): T.H.M. Vargas, L.H. Pulz, D.G. Ferro, R.A. Sobral, M.A.F.A. Venturini, H.L. Corrêa, R.F. StrefezziSummaryMalignant melanomas (MMs) represent 7% of all malignant neoplasms in dogs. Oral melanocytic neoplasms are often malignant and associated with poor prognosis. There are no universally accepted prognostic markers for canine oral melanoma. Galectin (Gal)-3 is a prognostic marker for human neoplasms such as thyroid, gastric, colorectal and prostate cancers. The protein is related to processes that favour cancer progression, s...
ConclusionsNon-tissue diagnosis of prostate cancer, while rare, is not outside normal clinical practice and is strongly associated with advanced patient age, higher clinical stage, multiple comorbidities, and very high PSA levels.
Conclusions: The self-reported benefits of physiotherapy for SUI symptoms did not differ significantly between the two types of prostatectomy surgery at 2 years post-surgery. PMID: 31719716 [PubMed]
CONCLUSIONS Eriocalyxin B induces apoptosis and autophagy involving the Akt/mTOR pathway in prostate cancer cells in vitro. These findings provide evidence for Eriocalyxin B as a potent therapeutic for the treatment of prostate cancer. PMID: 31714902 [PubMed - in process]
Contributor : Inge SeimSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe ghrelin receptor antagonist [D-Lys3]-GHRP-6 (or PBS control) was administered for two weeks to NOD/SCID mice with PC3 prostate cancer cell line xenografts. Daily intraperitoneal injections of 20 nmoles/mouse/day [D-Lys3]-GHRP-6 significantly reduced xenograft tumour size at day 9 to 14. RNA-sequencing was performed on xenograft tumours at experimental endpoint (14 days).